Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Telix Pharmaceuticals ( (AU:TLX) ) is now available.
Telix Pharmaceuticals has reported the cessation of several classes of equity-linked incentives, including 140,278 share appreciation rights, 1,957 deferred share rights, and 33,407 performance share appreciation rights, all effective 6 March 2026. The rights lapsed because performance or other conditions were not met or became incapable of being satisfied, or were cancelled by agreement, modestly reducing potential future dilution and slightly tightening the company’s issued capital profile for existing shareholders.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$31.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
More about Telix Pharmaceuticals
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company listed on the ASX under the code TLX. The company develops and commercialises radiopharmaceutical and oncology-focused therapies, targeting global markets for advanced diagnostic and therapeutic medical products.
Average Trading Volume: 2,907,027
Technical Sentiment Signal: Sell
Current Market Cap: A$3.73B
For a thorough assessment of TLX stock, go to TipRanks’ Stock Analysis page.